Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study.
Fiche publication
Date publication
mars 2022
Journal
World journal of gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE CARVALHO BITTENCOURT Marcelo
Tous les auteurs :
Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MC, Petitcollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L
Lien Pubmed
Résumé
Crohn's disease (CD) is complicated by perianal fistulas in approximately 20% of patients. Achieving permanent fistula closure remains a challenge for physicians. An association between serum anti-tumor necrosis factor-α concentrations and clinical outcomes in patients with CD has been demonstrated; however, little information is available on serum adalimumab (ADA) concentrations and remission of perianal fistulas in such patients.
Mots clés
Adalimumab, Clinical pharmacology, Crohn’s disease, Peri-anal disorders
Référence
World J Gastroenterol. 2022 Mar 7;28(9):961-972